Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder involving both upper and lower motor neurons that results in progressive weakness of skeletal muscles. Regardless of site of first onset, death usually occurs as a result of progressive respiratory muscle involvement, with 50% of patients dying within three years of symptom onset. Mechanical ventilation is becoming increasingly accepted in ALS. In Canada, noninvasive ventilation is the most common form of ventilation applied, with tracheostomy ventilation being very uncommon. The current guideline addresses respiratory muscle testing, the benefits of mechanical ventilation in ALS, timing of initiation of ventilation and modes, settings and place of initiation. It also reviews diaphragm pacing and respiratory muscle training. Finally, given the challenges involved with tracheostomy ventilation in ALS, the question of tracheostomy ventilation is addressed.
Introduction
The first Canadian Thoracic society (CTS) guideline for Home Mechanical Ventilation (HMV) was published in 2011 1 and included a section detailing recommendations for HMV for patients with Amyotrophic Lateral Sclerosis (ALS). This is the first update of the ALS section of that guideline and is intended for use as a standalone document making recommendations on the respiratory care of ALS patients. It excludes airway clearance and recruitment techniques in ALS and other neuromuscular disorders that were addressed in the 2011 guideline and that will be covered in an upcoming update by the CTS HMV clinical assembly. Airway clearance and recruitment are recognized to be of critical importance in the care of ALS patients.
ALS is a neurodegenerative disorder involving both upper and lower motor neurons that results in progressive weakness of skeletal muscles. Generally, onset of weakness is characterized as either limb or bulbar. Less commonly, approximately 3% of ALS cases in referral centres, the first presentation is with respiratory symptoms secondary to early respiratory muscle involvement. 2, 3 Regardless of site of first onset, death usually occurs as a result of progressive respiratory muscle involvement, with 50% of patients dying within three years of symptom onset. 4 Patients with bulbar onset ALS generally have a shorter survival than those with limb onset. 5 The rapid progression to death separates ALS from most other neuromuscular disorders (NMDs) for which noninvasive ventilation (NIV) and tracheostomy ventilation are considered. ALS is also distinct from other medical conditions for which chronic mechanical ventilation is provided, including other neuromuscular disorders (NMDs), by virtue of having the poorest survival using ventilation. In one case series, only 5% of ALS patients using mechanical ventilation were alive after five years, as compared to more than 60% of patients with other neuromuscular diagnoses. 6 Ninety-five percent of the ALS patients using home ventilation in the Swedish Home Mechanical Ventilation registry 6 were using it noninvasively, a number similar to data from the North American ALS CARE database, which has remained largely unchanged since 1996 when it was created. 7 Use of home ventilation is increasing despite some debate regarding the ethics of prolonging survival in such a rapidly progressive disorder with poor survival on NIV. 6 In 1999, Melo published a survey of multidisciplinary ALS clinics and found that only 15% of eligible patients were using NIV. 8 This number was similar to that reported in the ALS CARE database two years later. 9 The ALS CARE database was reviewed again in 2006, following many reports of positive outcomes with the use of NIV and found that 36.2% of patients considered to be candidates were using NIV. 10 A Canadian survey of ALS centres published in 2010 found that NIV was used by 18.3% of patients, while only 1.5% were reported as tracheostomy ventilated. 11 The increasing trend in use of NIV in ALS was highlighted by a 2012 publication reviewing the UK experience. 12 They noted a 3.4 fold increase in NIV use in ALS between 2000 and 2012. An Australian database reporting on a large cohort of patients with ALS found 23% of their patients between 1991 and 2011 received NIV. 13 Some countries have reported particularly high incidences of NIV use. A recently published Japanese study reported that 52% of their patients used NIV after 2000. 14 Finally, a single center report from Denmark also reported a high incidence of 42.3% treated with NIV between 1998 and 2012. 15 Although there may be variability in its use, the focus in the ALS literature now is not whether or not to offer NIV, but rather the optimal timing and criteria for initiation of NIV.
Differences from prior guideline published in 2011
This clinical practice guideline is an update from an earlier guideline that was published in 2011 by the Canadian Thoracic Society. 1 Changes in the content from the prior guideline include the following:
1. Further reports of the benefits of HMV. 2. New techniques to evaluate respiratory muscles are discussed, and reevaluation of previously reported respiratory testing. 3. Exploration of the rationale for earlier timing, with less focus on a cut off value for vital capacity. 4. Review and recommendations regarding respiratory muscle training in the ALS population. 5. More conclusive evidence regarding diaphragm pacing after publication of two randomized controlled trials (RCTs) showing negative outcomes.
6. Recommendation of mouthpiece ventilation as an option in a subgroup of ALS patients. 7 . Exclusion of any discussion of airway clearance in ALS.
This is recognized to be of critical importance, was addressed in the 2011 guideline, 1 and is currently under review by the HMV clinical assembly.
Target patient population
The current clinical practice guideline applies to all adult individuals with Amyotrophic Lateral Sclerosis who are at risk for or are using HMV.
Target users
The present clinical practice guideline is intended for use by the health care teams that care for individuals who are at risk for or require ventilatory assistance. Respirologists, physiatrists, neurologists, family practitioners, nurses, respiratory therapists, physiotherapists and other health care professionals can use this guideline to help inform their clinical practice with regard to HMV. This guideline is also intended for use by ventilator-assisted individuals (VAIs) and their caregivers to help them make informed decisions on HMV and by health care decision makers to aid in establishing policy and making funding decisions.
Guideline panel composition
The CTS HMV guideline panel was interprofessional and was comprised of HMV clinicians and health care professionals with content expertise. The panel was chaired by one author and included seven adult respirologists, one physiatrist specializing in neurorehabilitation and one registered respiratory therapist. All author conflicts of interests are posted on the CTS website at https://cts-sct.ca/guideline-library/. Patient and caregiver input was not sought in development of this guideline, which is a weakness of the current guideline and which will be corrected in the next update of this document.
Methodology
This clinical practice guideline was developed in accordance with the CTS guideline production methodology (https://ctssct.ca/guidelines). The panel utilized the AGREE II checklist 16 to guide the development of this guideline.
Selection of key clinical questions:
The primary author and the chair of the guideline panel determined key clinical questions based on their own knowledge of the literature and existing guidelines in the areas of benefits of mechanical ventilation in ALS; respiratory muscle testing and monitoring; timing of initiation of ventilation; modes, settings and place of initiation; diaphragm pacing; respiratory muscle training; and tracheostomy ventilation. Draft questions were then reviewed, discussed and revised by the panel with the final questions chosen to address significant changes since the last guideline, and gaps not addressed by prior guidelines in the area of ALS care. Using the PICO method, the panel took into consideration the Patient group or groups that should be addressed, the Intervention or interventions that should be examined, the Comparison groups that should be part of the studies of the various interventions and the Outcome or outcomes of interest. In the second part of the PICO process, panel members were asked to consider issues that influence implementability, when choosing PICO questions: the magnitude of the knowledge-tocare gap; target audiences; known barriers and supports to implementation; societal impact; and measurability of any implementation program. Members reached consensus on these questions over several teleconference meetings, webinars and email exchanges.
Literature search and screening of abstracts: An initial literature search was completed current to September 2017 using MEDLINE (OVID); Embase (OVID); HealthStar; the Cochrane Library: the Canadian Medical Association InfoBase; and the National Guideline Clearinghouse. The second literature search was conducted through to March 31, 2018 to include the most recent literature. Additional articles were found by review of the references in the articles accepted. Details of the search strategy are outlined in Appendix 1. The abstracts were assessed independently by two panel members for inclusion or exclusion and conflicts were resolved by discussion between panel members.
Study selection criteria: Following the completion of the abstract screening, the full text articles were retrieved and reviewed. Articles were selected for inclusion in the systematic review if they were directly relevant to one of the six PICO questions. All types of reports were considered and included guidelines, meta-analysis, systematic review, randomized controlled trial, cohort study, case control study, case series or case report.
Critical appraisal of identified studies: Data from all articles relevant to each PICO question were abstracted into tables by the lead author and can be found on the CTS website, at https://cts-sct.ca/guideline-library/. During discussion of each question via webinars held in June and July of 2018, the data were reviewed by the panel, and evidence addressing each clinical question was assessed according to the components of the GRADE 17 criteria (Table 1) . Synthesis of evidence-based clinical judgement of risk versus clinical benefit: For each clinical question, the panel considered the strength and directness of the published evidence supporting an intervention or treatment approach. The panel discussed the potential health benefit to the patient, the overall impact on the population burden of morbidity and mortality of ALS, and issues of risk, burden on a patient to adhere and cost effectiveness of an intervention or treatment. These discussions and the resulting synthesis of clinical judgement are presented for each recommendation.
Clinical remarks are included in association with each clinical question and are intended to offer experienced advice to the target user. Some of these good practice points may not have an evidence base, but are viewed as good clinical practice by the expert panel. All good practice points were arrived at by consensus, based on the clinical experience of the guideline panel members.
Formulation of recommendations and classification:
Following the open and extensive discussions and review of evidence for each PICO question, a draft recommendation was proposed. The strength of the recommendation was based on consideration both of the GRADE quality of evidence, and the expert panel's synthesis of clinical judgement. In accordance with CTS methodology, the recommendations were then reviewed by the CTS Canadian Respiratory Guideline Committee (CRGC) Chair to optimize the language of each recommendation with a view to improving intrinsic implementability. 18 Next, a recommendation consensus process was completed by electronic survey using a six-point voting scale (Table 2 ). For a recommendation to be accepted, it had to be voted on by 75% of the panel members and achieve ratings of "wholeheartedly agree," "agree" or "can support" by ! 80% of the voting panelists. In the event of a failure to reach this threshold, another period of discussion ensued, whereby dissenting opinions were heard and considered. The recommendation was then revised, followed by a second round of electronic voting using a three-point scale (Table 2) , with acceptance of a recommendation requiring ! 80% of the voting panelists choosing option 1 or 2. Through this process, all recommendations achieved acceptance, with a second round of voting required for only 3/22 recommendations.
Applicability
Facilitators and barriers to its application: The tools exist for implementation of the recommendations of this guideline. Equipment is readily available and provincially funded in Canada in most, though not all, provinces and territories and the minimum required monitoring can be performed in both large and small centres. Unfortunately, not all ALS patients are cared for in multidisciplinary ALS clinics and, in ALS clinics, the model of respiratory care is inconsistent. This may be a barrier to application.
Advice and/or tools on how the recommendations can be put into practice: Optimally, all ALS patients should be regularly followed in multidisciplinary ALS clinics with experienced respiratory therapists and respirologists; however, this may not be an immediately achievable goal.
Protocolizing follow up and respiratory monitoring for ALS patients, whether followed by individual respirologists, neurologists or family physicians, can identify patients requiring intervention leading to timely initiation of noninvasive and the positive outcomes detailed in this document.
Registered Respiratory Therapists (RRTs) are excellent resources and individual health regions should be encouraged to capitalize on their expertise. Busy respirologists have come to rely on RRTs in health regions where they are trained to initiate and monitor noninvasive ventilation in association with a clinic specializing in HMV. RRTs alert team members to changes in status and needs and can be an excellent "early warning" system of a failing respiratory status in the ALS population. Health regions should be lobbied to include experienced RRTs in their ALS clinics and home care teams. The RRT community resource can be used for other ventilated and at risk populations making it valuable for a larger number of individuals.
Potential resource implications of this guideline: Excellent and timely care of the ALS population has the potential to reduce acute care needs and overall cost to the system. The equipment is already currently funded in most jurisdictions and the equipment costs are minor when compared to inpatient admission costs. The cost of adding newer monitoring equipment (eg, Sniff Nasal Inspiratory Pressure monitor) is small and can be absorbed by most of the larger centres.
Monitoring and/or auditing criteria: As care of the ALS patient may be by individual neurologists, respirologists or ALS centres, it will be challenging to monitor adoption of the guideline. The most reliable data collection at present is by ALS clinics and by the Canadian ALS Research network and it is for this reason that a survey of awareness and compliance will be done through ALS clinics and the Canadian ALS Research network. At 12-24 months post publication and distribution, ALS clinics across Canada will be surveyed to assess their knowledge of and compliance with recommendations.
Review and approval process
In accordance with the CTS guideline review and approval process, before completion, CTS staff distributed the guideline for formal review by: 1) two international ALS content experts); and 2) two internal (CTS) reviewers with one reviewer performing an AGREE assessment of the guideline. The authors were blinded to the identities of the reviewers. The lead author considered AGREE II scores and reviewer comments, provided responses to the comments, and made corresponding changes to the manuscript. These reviews and the AGREE II scoresheet were provided to the CTS CRGC for review. The CRGC then reviewed these documents and provided further suggestions for edits that were considered by authors. The CRGC then recommended approval of a final draft of the guideline to the CTS Executive Committee. All reviews and author responses are posted on the CTS website at https://cts-sct.ca/guideline-library/.
Living guideline/future updates
The HMV ALS guideline PICO questions will be uploaded in the CTS/McMaster Database, whereby authors will use the continuously updated McMaster Plus database to review Cannot support -block it For a recommendation to be accepted, it has to be voted on by 75% of the eligible panel members and achieve ratings of wholeheartedly agree, agree, or can support by 80% of the voting panelists. If this is not achieved, additional discussion and revision of the recommendation(s) ensues, for which acceptance of a recommendation requires a majority (80%) for option 1 or 2.
new articles pertaining to these PICO questions published in top impact-factor journals as of April 2018. The studies are indexed according to the PICO questions, and made available to the guideline panel on a dedicated software platform for manual assignment to individual reviews. This evidence service will prompt guideline updates and facilitate year end reviews. The entire guideline will be reviewed every three years or sooner, to determine the need for guideline updates, in accordance with the CTS Living Guideline Model (details available at www.cts-sct.ca/guideline-library/). 
Summary of evidence

Survival
The only randomized controlled trial (RCT) of noninvasive ventilation (NIV) with survival as a primary outcome was published by Bourke et al in 2006. 19 They screened 121 patients and ultimately recruited 92 patients to be followed every two months until randomization, which occurred if they met one or both of the pre-defined criteria: orthopnea with Peak inspiratory pressure (PImax) less than 60% predicted or symptomatic daytime hypercapnia. Ultimately, 41 were randomized and the data analyzed for all patients and also subdivided into "better" or "poor" bulbar function. All patients using NIV showed a modest survival advantage from randomization to death over those patients randomized to standard care excluding NIV: 219 (range 75-1382) days vs 171 (1-878) days. The subgroup with "better" bulbar function showed a much larger survival advantage with NIV compared to controls: 216 (range 94-681) days vs. 11 (1-283) days. There were six deaths of nine patients in the control group with better bulbar function within two weeks of enrollment. Five of the six had severe respiratory muscle weakness at enrollment. The "poor" bulbar function group showed improvement in health-related quality of life (HRQoL) if receiving NIV, but no survival benefit: 222 (range 75-1382) days vs 261 (6-878) days. The mean duration of daily use in this group, however, was less than four hours. In addition, the numbers were small and not powered to show survival benefit in the subgroup with poor bulbar function.
The Cochrane database of systematic reviews recently updated their review of mechanical ventilation in ALS in 2017 20 and found no new RCTs in this population addressing survival, disease progression or HRQoL. At the conclusion of their review, they commented that "more RCT evidence to support the use of NIV in ALS will be difficult to generate, as not offering NIV to the control group is no longer ethically justifiable." They commented that future studies should focus on the timing of initiation of NIV for maximal benefit.
Other prospective studies 6, [21] [22] [23] 24 and retrospective studies [13] [14] [15] [25] [26] [27] have reported prolonged survival in those using NIV. None of these studies was randomized, although attempts were made to provide a control group. The controls included patients refusing or intolerant of NIV or those using NIV less than 4 hours/day. 13, [22] [23] [24] 26, 28 Historical controls were also considered. 29 An Australian group 13 reported the largest cohort of patients (n ¼ 929), 23% of whom received NIV. They found a survival advantage in patients treated with NIV, surviving 28 months from symptom onset as compared to 15 months in those who did not receive NIV. Interestingly, the subgroup demonstrating the clearest survival benefit was the bulbar onset group with a 19 month survival advantage, which is in contrast to most other studies reporting NIV outcomes in patients with severe bulbar dysfunction. One other recent study did, however, report a clear survival advantage in patients with severe bulbar dysfunction. 24 Numbers of bulbar patients were small (n ¼ 15 NIV vs n ¼ 6 controls) in this study. The control group was comprised of patients declining NIV. More severe bulbar dysfunction, as measured by the Norris Bulbar Score, was a prognostic factor in NIV failure, although a cut off value of the Norris Bulbar Score was not suggested. Despite this, prolonged survival from disease onset was found in the severe bulbar group with NIV: 40 months in the NIV group vs 16 months in those refusing NIV. This suggests that those accepting and tolerating NIV with severe bulbar dysfunction show a significant survival benefit.
The survival benefit was modest in most of the reported studies; however, in one retrospective descriptive study reported by Bach's group 27 the survival benefit in a subgroup of patients with preserved bulbar function could be measured in years even when requiring continuous NIV.
Quality of life
In the single RCT of NIV in ALS, 19 improved HRQoL was reported for patients randomized to NIV compared with standard care with no NIV. For those with "better" bulbar function, NIV resulted in large improvement across several measures of HRQoL when compared to controls. Patients with "poor" bulbar function randomized to NIV also showed improvement in HRQoL, although the improvement was less marked.
In other prospective studies reporting HRQoL, 21, 23, [30] [31] [32] [33] authors consistently reported improvements in HRQoL in certain domains for patients using NIV. These included sustained improvements in mental health, energy/vitality, social isolation, fatigue and mastery. Physical function domains generally worsened as would be expected with disease progression.
Gas exchange and pulmonary function
All studies reporting gas exchange after initiation of NIV 31, 32, [34] [35] [36] show reduction of daytime partial pressure of carbon dioxide (pCO2) after initiation of nocturnal ventilation.
Five studies have reported the rate of decline of vital capacity (VC) before and after initiation of NIV.
13,23,27,28,30 Four of these studies 13, 27, 28, 30 showed a slowing of decline of lung function after successful initiation of NIV, while in contrast, one study 23 reported a decrease in VC after initiation of NIV.
Sleep
There are many reasons for sleep disruption in patients with ALS. Limited ability to change body position, pain and anxiety may all be factors. As with other neuromuscular disorders that involve respiratory muscles, sleep fragmentation by breathing related arousals has been reported. Early studies looking at sleep in patients with ALS sought to characterize the nature of the sleep disturbance that occurred, with recent studies looking more systematically at the effect of NIV on sleep parameters and HRQoL. Seven early studies that characterize breathing related sleep abnormalities specifically in patients with ALS 25,34,37-41 reported a decrease in total sleep time and sleep efficiency, increased stage 1 sleep and reduced REM sleep. The predominant pattern of sleep disordered breathing was not obstructive apneas, but rather, mixed apneas, central apneas and hypoventilation. Among these studies patient selection varied widely. In two of the studies, 25, 34 patients selected had more advanced disease, with either very low VC (mean 52%) or symptoms suggesting sleep disordered breathing. Patients in other studies were asymptomatic 39 or had normal pulmonary function and diaphragm function. 41 Given bulbar involvement by ALS, the possibility of upper airway obstruction during sleep has been raised. Ferguson et al 38 found obstructive apneas did not occur; however, other investigators have noted obstructions in some subjects. [42] [43] [44] In four of the seven early studies, 25, 34, 37, 38 at least one subject was treated with NIV. Observations included improvement in sleep architecture, decreased breathing related arousals, improved oxygenation during sleep and improved symptoms related to sleep disordered breathing. In another, 31 cognitive impairment improved after NIV and was assumed to be related to correction of sleep disordered breathing.
More recent studies have reported the effect on HRQoL and sleep parameters with NIV. Sustained improvement in the Epworth Sleepiness Scale (ESS) and Pittsburg Sleep Quality Index (PSQI) and some subscales of the McGill QoL (MQoL) questionnaire were found and scores did not fall below baseline despite worsening ALSFRS scores. 36 One author 42 reported on the effect of NIV on sleep and showed that the minimum saturation improved by 7% with NIV. Time spent <90% also improved with NIV though other sleep parameters showed no significant change (sleep efficiency, AHI, arousal index or sleep architecture). Another report 45 found that those with bulbar dysfunction had better quality sleep at baseline with less change noted after NIV initiation compared to non-bulbar patients. PSQI did improve in bulbar patients though improvements in ESS, and MQoL were observed only in non-bulbar patients. In the entire cohort, N3 sleep and REM increased and arousal-awakening index (AAI) improved. The short form survey (SF-36) emotional health subscale also improved. A later report by the same authors 46 studied patient ventilator asynchrony, leaks and sleep quality. They noted the commonest asynchrony was ineffective efforts and that despite meticulous titration, patient ventilator asynchrony and leaks persisted, although interestingly, had a minor impact on sleep. 
Respiratory testing
Measuring lung function in ALS serves two purposes. First, it has been shown that some measures of lung function are better predictors of survival than functional rating scales. 5, 6, 47, 48 This information could facilitate the design of studies evaluating new therapies, such as medications, in order to enrich the study population, possibly requiring fewer patients to achieve significance and aid in sample size calculations. Second, monitoring lung function helps guide the timing of interventions such as initiation of NIV.
Earlier literature focused on measures of lung function which predicted daytime hypercapnia, a logical criterion to initiate mechanical ventilation. More recently, however, there has been a focus on predicting nocturnal sleep disordered breathing for the purpose of earlier initiation of ventilation before onset of daytime hypercapnia with the goal of improving outcomes such as survival or HRQoL.
An earlier study looked extensively at predictors of daytime hypercapnia. 49 It assessed VC, FEV1, peak inspiratory pressure (PImax), peak expiratory pressure (PEmax), sniff transdiaphragmatic pressure (Pdi), sniff esophageal pressure (Poes), sniff nasal pressure (SNP), cough gastric pressure (Pgas), bilateral cervical magnetic stimulation (CMS) Pdi and arterial blood gas (ABGs). Sniff Pdi and CMS Pdi had the greatest predictive power for the presence of daytime hypercapnia. Of the less invasive tests, Sniff nasal inspiratory pressure (SNP) had the best predictive power. This predictive power was limited to those patients without significant bulbar dysfunction. No test reliably predicted hypercapnia in the patients with bulbar dysfunction.
Hypercapnia, though a relatively late finding, remains an indication for initiation of HMV and can be determined by ABG, or capillary blood gas 50 or transcutaneous CO2. 51, 52 A more recent assessment 53 of the predictive power of invasive and noninvasive respiratory muscle strength assessments for survival or ventilator free survival showed that VC had a good predictive power, but the cutoff value for a good outcome was in the normal range (>80% predicted) for all time intervals beyond 3 months. Although all tests of muscle strength predicted ventilator free survival, they had varying sensitivities. Sniff and Twitch transdiaphragmatic pressure were the best performing tests for ventilator free survival, although SNP also was shown to have a good predictive value. Maximal expiratory pressure (MEP) and MEP% predicted were also useful predictive tests. Supine forced vital capacity (FVC) was not assessed.
SNP has gained popularity in assessing the respiratory muscles as it is more sensitive to early muscle weakness than FVC 54 and can be performed by most patients, even those with advanced disease and bulbar dysfunction. 55 A SNP less (reduced strength 1 * ) than -40 cmH2O was shown to be significantly correlated with nocturnal hypoxemia and patients at this level had a median survival of only 6 months. 54 A more recent study 56 looked at SNP and other measures of lung function, including FVC, for predicting death at one year. A SNP < -50 cmH2O was more likely to be associated with death at one year and a SNP of > -70 cmH2O resulted in improved survival at one year. Ultimately a SNP cutoff value of -34 cmH20 was found to have a sensitivity of 0.75 and a specificity of 0.72 for death at one year. The highest risk of death at one year was found in those with a sniff nasal pressure -18cmH2O. By comparison, the cut off value for FVC to predict death at one year was high at 75.9% and was less predictive for death at one year than SNP.
Maximal inspiratory pressure (MIP) is also a sensitive measure of early muscle dysfunction and can be used as the disease progresses to predict survival, but requires the patient to tolerate and be able to seal around the mouthpiece, or mask in order to perform the test. 53, 57 Sitting VC is an insensitive measure of respiratory muscle weakness as it may remain normal even when respiratory muscle weakness is present. However, in one older study, when FVC falls to less than 50% predicted, survival was limited to nine months with most patients dying by six months. 47 Other authors have also noted the poor prognosis of patients with FVC < 50% predicted 48, 58 and, therefore, it is recognized that FVC, when very low, is specific for impending respiratory failure and death. It has become increasingly recognized that sitting FVC or SVC are not the best predictors of muscle weakness and impending respiratory failure given that FVC may be normal or near normal when other measures of respiratory muscle strength may be significantly abnormal. 53, 56, 59 More sensitive to respiratory muscle weakness and diaphragmatic dysfunction, in particular, is supine VC. A correlation between the percentage fall in VC from the erect to the supine position and the lowest saturation during REM sleep 60 suggests that a drop in VC from the erect to the supine position may be used to predict abnormalities in breathing during sleep associated with diaphragm dysfunction. Others have found that the change in VC from the erect to supine posture correlates well with symptoms of dyspnea, orthopnea and daytime fatigue. 61 A normal supine FVC was highly predictive of survival at 2 years. 62 Another author found a Borg dyspnea scale !3 when supine to be a useful predictor of a SNP -40 cmH2O and impending respiratory failure. 63 Rate of decline of Slow Vital Capacity (SVC) has also been assessed 64 and shown to be strongly correlated with rate of decline of SNP and respiratory symptoms. The probability of respiratory failure free survival was estimated in this study by the rate of decline in the SVC suggesting that this is a useful prognostic tool. The finding of rate of decline of respiratory tests as a prognostic tool was confirmed by another study, 57 which looked at decline in VC, MIP or SNP, MEP and PCF and showed that the risk of death is significantly associated with the decline in pulmonary function regardless of the PFT parameter followed.
More recently the amplitude of the action potential with phrenic stimulation has been correlated with pulmonary function tests, symptoms and survival at one year. 65 When the amplitude of the action potential (Pamp) was < 0.3mV, the median survival was 1.07 years as compared to a Pamp > 0.3mV of greater than 2 years. It was also found that a Pamp < 0.3mV correlated with symptoms of dyspnea, orthopnea and tachypnea. This threshold value of Pamp was also correlated with reduced FVC, MIP and SNP. Another study 66 also found that an abnormal Pamp was a predictor of death using a cutoff value of 0.4mV with a HR of 1.653 for those with a Pamp of <0.4mV. This is a non-volitional test and could aid in defining populations for future interventional studies in ALS.
Given the difficulty with volitional tests in this population, in particular the bulbar predominant patients, other non-volitional tests have been investigated. Diaphragm thickness by ultrasound has been found to correlate with other tests of respiratory function and to the compound muscle action potential (CMAP) of the diaphragm. 67, 68 This correlation, unfortunately, was less evident in patients with bulbar dysfunction and relatively mild symptoms, a population in which it may have been particularly helpful.
Lung function is essential in the follow-up of ALS patients, but equally important is a history that focuses on symptoms of dyspnea, orthopnea, poor sleep, excessive daytime sleepiness, morning headache and fatigue. The onset of dyspnea and rate of decline of VC predicted survival in one series. 69 Excessive daytime sleepiness and poor sleep were very good in predicting sleep disordered breathing, though not specific enough to use alone. Finally, orthopnea was found in one study 34 to be a good predictor of sleep disordered breathing. An excellent review of Respiratory measures in ALS was recently published by Lechtzin et al, which summarizes much of the aforementioned information. 70 
Timing of initiation of NIV
Early studies demonstrating the benefit of NIV in ALS patients with daytime respiratory failure have questioned whether earlier initiation of ventilation improves rate of decline in respiratory function, survival and HRQoL. Investigators have sought to define the optimal timing of initiation of NIV to maximize benefit.
Five earlier studies 29, 30, 33, 69, 71, 72 addressed the issue of timing. Many other studies speak indirectly to this question as the indications for initiation of ventilation may include symptoms alone without the requirement for an abnormal measure of lung function or hypoventilation. 22, 23, 26, 28, 30 Orthopnea is often the symptom for which ventilation is started. [21] [22] [23] 25, 26, 71 A study by Bourke et al. 30 supported initiation of ventilation for symptoms. They reported the greatest benefit and compliance in patients who complained of orthopnea. Also, in support of symptoms as an inclusion for initiation, they reported that four patients were initiated on NIV for the sole indication of nocturnal desaturation without symptoms. Of the four patients, only one was compliant with NIV and continued to use it.
A study exploring earlier initiation of NIV looked retrospectively at the survival of patients in whom NIV was started when FVC was greater than 65% predicted. 72 There were 67 patients in the standard therapy group and 25 in the early initiation group. There was a survival benefit from time of diagnosis to death in those starting NIV with FVC > 65% of predicted. Of note, however, the authors comment that patients in the "early" group frequently, though not always, had pulmonary function or ABG abnormalities that would have qualified them for NIV by other conventional measures.
In another study, 29 historical controls who received NIV for diurnal respiratory insufficiency were compared to ALS patients screened every three months with nocturnal oximetry and initiated on NIV when they demonstrated more than 15 periods of nocturnal desaturation per hour. The authors reported that survival was improved if NIV was started with evidence of nocturnal sleep disordered breathing, and prior to daytime blood gas abnormalities. However, for the subgroup with bulbar dysfunction, there was no survival benefit. The concept of NIV applied for nocturnal desaturation to improve survival, lead to studies which attempted to predict the presence of nocturnal disordered breathing or nocturnal desaturation or hypoventilation allowing for earlier initiation. Polygraphy was compared to FVC and symptoms. 59 This investigation suggested that the correlation between symptoms or FVC and the presence of nocturnal hypoventilation, as defined by prolonged desaturation or a nocturnal capillary pCO2 > 45, was poor. Eight of their 131 patients had FVC < 50% predicted and demonstrated no hypoventilation. In contrast, 14 of the 29 patients with FVC > 75% of predicted with no symptoms of dyspnea, demonstrated nocturnal hypoventilation. It is not clear whether treatment of these asymptomatic patients with a normal or near normal FVC who demonstrate nocturnal hypoventilation will improve their survival or QoL.
A recent pilot, placebo controlled study looking at early NIV 73 demonstrated the feasibility of use of sham ventilation in their study design. They defined early as FVC > 50% and demonstrated no difference between groups in their study though, to ensure tolerance, pressures were very low with an inspiratory positive airway pressure (IPAP) of only 8 cm.
Timing of NIV initiation has also been indirectly addressed by the recent literature which focused more on patient factors or testing that predict survival with NIV, predictors of tolerance to NIV, the effect of NIV on sleep and models for initiation of NIV which improve outcomes. 36, [42] [43] [44] [45] 74, [75] [76] [77] These studies imply both indications and timing that should be used for ventilation by demonstrating positive outcomes with the protocols applied.
Monitoring post initiation of NIV
Assessment of successful NIV has historically involved improvement in symptoms and gas exchange. More recently device download and assessment of nocturnal saturation or tCO2 have been reported. Two recent papers 43, 44 focused on the effect of NIV in correcting nocturnal desaturation and obstructions on survival. In both studies, device download was a component of post initiation monitoring of successful ventilation. One study 43 found better survival in those with a saturation >90% for >95% of the night while on NIV when assessed at 1, 3 and 6 months after initiation. If the study participant was found to have persistent desaturation at 1 month after initiation of NIV, changes were made in an attempt to correct the desaturation. This was reassessed again at 3 and 6 months. In those that were corrected at 1, 3 or 6 months, survival was reported to be the same as those who were well ventilated at 1 month. Device download assisted in the evaluation of the leak, which was a component in the correction. In the subset of patients who could not be corrected, survival was shorter. A follow-up study 44 looked at obstructions as a cause for desaturations and found that those with persistent obstructions had a shorter survival than those without obstructions. This was the case even if the obstructions were not associated with desaturation. They concluded that the effectiveness of ventilation is important to survival. A single parameter has not been identified as the most useful or predictive respiratory measure. Regular monitoring has been recommended to follow the decline in respiratory muscle function with most studies recommending repeated testing every 3 months. Recognizing the differences in rate of disease progression, regular monitoring every 2 to 6 months would be recommended. Nocturnal monitoring prior to initiation of NIV may be helpful in determining timing of NIV initiation though there is currently inadequate evidence to support regular and repeated nocturnal monitoring as part of routine follow-up. Follow-up with nocturnal assessment of oxygen saturation and device download to determine effectiveness of ventilation may prolong survival if effective ventilation can be achieved.
Section 3. Tracheostomy ventilation in ALS
Optimal timing for NIV for maximal benefit has yet to be determined. Current literature supports initiation for the indications listed in PICO 2.2 recommendations.
PICO 2.1: What type of testing is required to predict survival, respiratory failure or need for home mechanical ventilation/non-invasive ventilation?
Recommendations: 1. We recommend regular monitoring of ALS patients every two to six months from time of diagnosis (consensus based), depending on the anticipated rapidity of disease progression, including the following: Recommendations: 1. We recommend that practitioners offer NIV to patients with any one of the following: (a) Orthopnea * (GRADE 1B) (b) Daytime arterial or capillary pCO2 > 45 mmHg (GRADE 1B) (c) Sleep disordered breathing as defined by oxygen saturation < 90% for > 5% of the night or < 88% for 5 consecutive minutes or a 10 mmHg increase in TcCO2 during sleep AND any of the following symptoms: dyspnea, morning headache, daytime sleepiness, or non-refreshing sleep.
(GRADE 2B) (d) FVC < 50% predicted ** (GRADE 1B) (e) FVC sitting or supine <80% predicted with symptoms as indicated in Recommendation 2.1 (a) and any other indicator of respiratory muscle involvement including SNIP <-50cmH2O, or MIP< -65 cmH2O in males and < -55 in females. (GRADE 1C) (f) SNP < -40 cmH2O or MIP < -40 cmH2O ** (GRADE 1C) 2. We recommend follow-up assessment of adherence and adequacy of ventilation within the first month and as indicated by symptoms and to include device download and nocturnal oxygen saturation (and TcCO2 when available). *** (GRADE 2C)
* Clinical remark: Orthopnea may not be as specific for NIV initiation in individuals with significant bulbar weakness. If orthopnea is felt to be secondary to secretions in the setting of bulbar dysfunction, the secretions should be managed first.
** Clinical remark: A FVC < 50% or SNP/MIP<-40cmH2O have been shown to be a predictor of death at 6 months and are therefore considered to be an indication for NIV. Clinical judgement is required if there are no associated symptoms or the reliability of the values is questionable.
*** Clinical remark: The intention of device download review and monitoring of nocturnal oxygen saturation or TcCO2 (when available) is to correct leak, prevent excessive triggering (work of breathing), assure adequate volumes, prevent apneas and oxygen desaturation, and hypoventilation.
Historically, ventilation, if it was provided to ALS patients, was delivered via tracheostomy. Since the introduction of NIV, tracheostomy ventilation is less common and thought to be a less desirable option; 78 however, rates of tracheostomy ventilation throughout the world vary widely. The highest rates are seen in Japan and other Asian countries and are reported to be 27-45% of ALS patients, [79] [80] [81] although a recent Italian study also reported a high rate of 31.3% in one region. 82 Lower rates are generally reported in American and European databases 6, 7 and Canada reported a rate of 1.5% in 2010. 11 In studies reporting tracheostomy ventilation in ALS, the proportion of patients undergoing tracheostomy after advanced care planning varies from 0% to 63.5% 78, [83] [84] [85] [86] [87] [88] [89] and survival also varies. One study 84 reported a mean survival from tracheostomy of 30.3 months, while another 82 reported a survival with tracheostomy ventilation from disease onset of 47 months. One group compared survival depending on choice of intervention 79 reporting survival from disease onset as 32 months with no ventilation, 48 months with noninvasive ventilation alone and 74 months if tracheostomy ventilation was accepted. Similarly, comparing survival between different therapies, another group 15 reported a survival of 22.9 months with no ventilation, 25.8 months with NIV alone, 56.8 months if initial NIV was followed by invasive ventilation and 33.8 months if invasive ventilation alone was used. Although reporting of survival varies from time of onset of disease, from time of diagnosis or from onset of ventilation making comparison more difficult, these reports suggest that tracheostomy ventilation can prolong survival.
Although chosen in advance by some, tracheostomy may result from an acute deterioration and intubation when a personal advance directive is unavailable. Following tracheostomy for acute respiratory failure, one group 84 reported that none of the patients died in hospital; however, 70% were discharged completely ventilator dependent, and 28% partially ventilator dependent. Only one patient was liberated from mechanical ventilation. None of the patients had their tracheostomy removed. An Italian study 85 reported on 134 patients with tracheostomy ventilation over a 10-year period. This represented 10.6% of their ALS population during this period. Of those patients receiving tracheostomy ventilation, 56% were considered to be elective. A total of 20.1% died before discharge from the hospital and 48.5% were discharged home with a relatively short survival post tracheostomy. For those patients surviving the first 30 days, the median survival was 339 days from tracheostomy. They found survival dependent on age, marital status, follow-up in an ALS center, the discharge destination, and duration of disease before tracheostomy.
Bach has described decannulation after tracheostomy for acute respiratory failure in a select group of ALS patients with preserved bulbar function and the ability to generate an assisted PCF of >160 L/min. 27, 90 More recently, the same authors reported successful extubation regardless of measured PCF in patients with various NMDs, although this study included few patients with ALS. 91 Despite these occasional reports and the possibility of an extended period of NIV after decannulation, tracheostomy may be required in the future as bulbar function deteriorates, and if patients choose invasive ventilation in the hope of prolonged survival.
Concern has been raised regarding the patient and caregiver satisfaction with tracheostomy. In a retrospective review of patients using tracheostomy ventilation, an older American study found that 90% of patients were happy with their decision of tracheostomy and 94% of caregivers felt this way as well. 92 A 3-year survival of 58% was reported, with a five-year survival of 33% in this series of patients. A study comparing HRQoL of both patients and caregivers supported with either tracheostomy ventilation or NIV, found a good overall HRQoL in patients, but a very high burden of care for tracheostomy ventilated caregivers, 30% of whom rated their own HRQoL lower than the patient's. 83 Vianello et al 84 reported on a cohort of 60 patients who were invasively ventilated after an episode of acute respiratory failure. Thirteen of these patients participated in an assessment of HRQoL completing the Life Satisfaction Index (LSI-11) and Beck Depression Inventory (BDI). The cumulative score on the LSI-11 was 9.3, which was similar to a group of ALS patients without tracheostomy and to that of the general population. Fifteen percent were found to be severely depressed as assessed by the BDI. Eleven of the 13 patients completing the questionnaires reported that they would choose to have a tracheostomy if they had to make the decision again. This may be a biased sample, however, given this included only 13 of their 60 patients completing the questionnaire.
In the prior publication of this guideline, the section on clearance recommended deflated or uncuffed tracheostomy tubes when possible. A recent study 89 looked at the type of tracheostomy tube required for effective ventilation in ALS. It found that 35.7% of patients with advancing bulbar dysfunction required a cuffed tube as a result of excessive air leak and hypoventilation though the majority was able to use uncuffed tubes. 
Conclusions
Tracheostomy ventilation remains an option in carefully selected patients after lengthy discussion of the implications. It is strongly preferred that these discussions occur well in advance of acute respiratory failure. Tracheostomy ventilation can prolong survival in ALS and can provide an acceptable QoL for some patients. It does, however, impose a high burden for caregivers.
Recommendations:
1. We suggest that practitioners discuss the option of tracheostomy ventilation with ALS patients. (GRADE 2B) 2. We strongly recommended that practitioners discuss this option well in advance Ã of acute respiratory failure. (GRADE 1C)
* Clinical Remarks:
Tracheostomy ventilation should be discussed with patients with ALS early in the disease and reviewed during disease progression as patients may revise their wishes with symptom progression. These discussions should occur well in advance of an acute indication such as lower respiratory tract infection which may acutely worsen respiratory status. Though tracheostomy is an option, in our experience, few ALS patients choose this option given that NIV can be applied even with advancing respiratory muscle dysfunction and given that care needs with tracheostomy are likely to require institutionalization or impose a high burden for home caregivers. If tracheostomy ventilation is chosen, discussions should occur early on with patients and families to establish the conditions under which ventilation will be withdrawn (eg, If a "locked in" state occurs.) Section 4. Respiratory muscle training in ALS PICO 4: Does respiratory muscle training as compared to standard care improve:
1. physiologic parameters 2. survival 3. rate of progression of disease 4. time to ventilation
The role of exercise in ALS remains unclear. There has been concern that compensatory overuse of surviving muscle groups may worsen neural dysfunction and potentially accelerate the loss of motor units. 93 In contrast, other studies have suggested that exercise may be safe and effective in slowing the decline in muscle strength. [94] [95] [96] Inspiratory muscle training has been investigated in other neurological diseases such as spinal cord injury 97 and Duchenne muscular dystrophy, 98, 99 but the results of these studies may not necessarily be relevant to a rapidly progressive degenerative neurological condition.
In a 2008 cohort study of ALS patients looking at a specific breathing pattern accentuating the diaphragmatic component of inspiration (Yoga breathing), 100 outcomes included QoL and FVC rate of decline. Patients served as their own controls with a 3 month run-in period measuring FVC monthly. They had difficulty in recruiting and, ultimately were able to analyze data from only 8 subjects. They found no improvement in FVC, QoL or rate of decline in FVC over 12 weeks.
A double blind RCT performed to address the question of safety and efficacy of inspiratory muscles training in ALS 101 recruited only 19 patients after screening 37 patients and looked at multiple outcomes including FVC, VC, SNIP, MIP, capillary blood gas, SF-36, ALSFRS-R and 6MWT. Although trends to improvement were seen, they found no significant difference between the groups and noted improvements in the MIP in both the training group and the control group. QoL was not impacted.
One trial looked at inspiratory muscle training (IMT) in ALS patients with early disease as defined by FVC > 70% predicted, MIP > 50% and an ALSFRS-R >24/40. 102 The trial design used a delayed intervention group as the comparator group. Group one started training at the onset of the study and group two started IMT 4 months after group one. The study lasted a total of 8 months. Their primary outcome was the ALS functional rating scale (ALSFRS) with secondary outcomes including multiple measures of respiratory function and QoL. There was no significant difference between groups in the ALSFRS or any other measure of respiratory function with the exception of the MVV, which was significantly different only at 4 months. Dyspnea was assessed using a visual analog scale and did not differ between groups. QoL showed no difference between groups using the Euro-QoL-5D questionnaire. There was also no difference in depression, fatigue or functional status, all assessed by questionnaires. In an extension of this study that included 18 patients from both groups 1 and 2, survival was measured and compared to historical controls. 103 The IMT group had a significantly longer survival from symptom onset than the historical controls: 36.99 months in the IMT group, 24.06 months in the historical controls.
Finally, the impact of expiratory strength training in ALS was studied in a delayed intervention open label trial. 104 After enrollment, there was a five week period during which no training occurred. Their primary outcome was MEP with secondary outcomes including analysis of swallowing, cough and aspiration risk. There was a significant increase in MEP and in maximal hyoid elevation after 5 weeks of treatment, but no change in cough or other parameters of the swallow assessment.
A systematic review 105 and a meta-analysis 106 have been published looking at the question of benefit of respiratory muscle training in ALS. The earlier systematic review 105 found no convincing evidence of benefit. The subsequent meta-analysis 106 looked at studies that included both ALS and Multiple Sclerosis patients. They found that MIP, MEP and FEV1 improved without change in FVC. Caution is recommended in applying this study to the ALS population given the small number of ALS patients included in the meta-analysis.
It is of note when reviewing the individual studies that the nature of the training varied from study to study in duration, intensity and training protocols. It can be noted that there did not appear to be harm associated with respiratory muscle training. 
Conclusions
No convincing evidence was found to support improved physiologic parameters, longer survival or slowing in rate of progression of disease using respiratory muscle training. Delay in time to ventilation was not assessed. Small numbers of patients were included in the studies.
Recommendation:
1. We do not suggest respiratory muscle training in ALS patients.
(GRADE 2C)
Clinical remark:
There does not appear to be harm associated with respiratory muscle training.
Section 5. Diaphragm pacing in ALS PICO 5: As compared to standard care, does diaphragm pacing, with or without concurrent noninvasive ventilation:
1. Prolong survival 2. Delay the time to requirement for noninvasive ventilation 3. Slow disease progression or 4. Improve QoL?
A system for diaphragm pacing, which inserted electrodes into the inferior surface of the diaphragm adjacent to the motor end points to stimulate diaphragm contraction, has been developed primarily for ventilator dependent spinal cord injured patients. It was hypothesized that stimulating intact motor units in the diaphragm of ALS patients may prevent atrophy and slow rate of decline of respiratory muscle weakness resulting in improved survival or delayed time to ventilation. A pilot trial began implanting ALS patients in 2005 and subsequent reports of this surgical cohort suggested slowing in the rate of decline of FVC which was extrapolated to improvement in survival. 107 In 2012, 8 ALS patients paced with this pacing system were reported and compared to 354 patients that were not treated with pacing. 108 Poor tolerance was found to pacing, with 6 of their 8 patients decreasing the pacer settings and 4 of the 8 stopping pacing entirely. They also noted more rapid decline in VC and a shorter survival when compared to their cohort of ALS patients referred between 1996 and 2011.
Two RCTs of diaphragm pacing in ALS have now been reported.
The DiPALS study 109 compared NIV plus pacing (n ¼ 37) to NIV alone (n ¼ 37) with initiation when respiratory insufficiency was present as defined by one or more of the following: a VC 50-75% predicted, SNIP<-65cm H2O in men and -55cm H2O in women in the presence of symptoms, SNIP <-40, or pCO2 > 6kPa in the day or 6.5kPa at night or nocturnal desaturation. A total of 37 patients were enrolled in each arm. Their primary endpoint was survival from randomization to death. They also reported survival from symptom onset, QoL, compliance and adverse events. The study was terminated prematurely when the Data Monitoring and Ethics Committee noted a concerning signal in overall survival figures. They found that survival from symptom onset in the paced plus NIV group was 28 months as compared to NIV alone, which was 45 months. The patient health utility score (EQ-5D-3L) was slightly lower with pacing, although other HRQoL questionnaires were similar between the two groups. They concluded that diaphragmatic pacing should not be a routine treatment for ALS patients in respiratory failure.
The RespiStimALS study 110 enrolled patients that did not require NIV and had FVC 60-80% of predicted with evidence of diaphragm function with a phrenic stimulus. Patients meeting these criteria were randomized to receive pacing or standard care with initiation of NIV in both groups when an indication occurred. All patients had pacer insertion soon after enrollment with the control group receiving an inactive cable and sham pacing. When criteria for NIV were met, the treatment was unmasked and all patients received both pacing and NIV. NIV was initiated when FVC <50% predicted, pCO2 > 45, MIP or SNIP < 60% predicted, or nocturnal hypoxemia with 5% of recording time <90% or 5 consecutive minutes below a saturation of 88%. Decision to initiate NIV was established by an independent allocation committee. 37 patients were in each group. The study was terminated early by the study independent safety committee after becoming aware of the results of the DiPALS study and calling for a formal unplanned masked interim survival analysis which showed a mortality difference. The primary outcome was NIV free survival from randomization. They also reported survival from symptom onset, QoL and rate of decline of FVC, MIP and SNP. The median NIV free survival from randomization was 6.0 months in the early paced group and 8.8 months in the standard care group. Median survival from symptom onset in the early paced group was 51 months and this endpoint was not reached in the sham paced group. There was a more rapid decline in FVC, MIP and SNP in the early pacer group. QoL was not different between the two groups. It is interesting that the "pacer use" was higher in the sham group at the time of NIV initiation suggesting possible poor tolerance in the active pacing group. The authors concluded that there was no benefit to early pacing in terms of delay to NIV requirement or QoL and that it decreased survival.
These two RCTs both concluded that diaphragm pacing has no benefit and, in fact, may be harmful with a more rapid decline and shortened survival. The mechanism is unknown though both authors speculated on reasons for their findings. These studies are in contrast to the earlier positive reports in the surgical cohort studies. Both authors speculated that the 3 month run in period in the surgical cohort may have selected for patients with a slower disease progression, given that those with more rapid decline may have been excluded after the run-in period.
Box 5. Diaphragm pacing in ALS PICO 5: As compared to standard care, does diaphragm pacing, with or without concurrent non-invasive ventilation: In three older studies examining the benefit of NIV in ALS, both pressure and volume capable ventilators were used in the same study 22, 23, 71 implying that the authors considered the two modes were equivalent for the purpose of assessing benefit. Studies comparing the two modes have been reported in mixed populations. [111] [112] [113] [114] One study 113 included both restrictive and obstructive diseases, each having different respiratory mechanics. The conclusion of these studies reporting on mixed groups was that either mode is appropriate for use in most patients. It is interesting to note that in this study, approximately one-third of the patients were bilevel "non-responders" with elevated PCO2 and reduced nocturnal saturation when treated with Bi-level. In this study, "non-responders" were returned to volume ventilation. The conclusion was that the majority of patients successfully treated with volume-cycled ventilation could also be adequately maintained on pressure controlled ventilation; however, data showed that some were less well ventilated on pressure ventilation and required a volume targeted mode. In other studies comparing the two modes of ventilation, authors report a patient preference in some. Bach proposed volume cycled ventilators in one study looking at noninvasive support in the ALS population given that the ventilator could then be used to breath stack to Maximal Inspiratory Capacity (MIC) as an aid to airway clearance. 27 A more recent study 115 investigated whether the mode of noninvasive ventilation affected survival, gas exchange, and clinical outcomes in ALS. A French center using pressure targeted NIV was compared to a Spanish center using volume cycled NIV. The primary outcome was survival and there was no difference between centres. Symptom control appeared better with volume control NIV as well as gas exchange, time spent nocturnally with a saturation of less than 90%, mean saturation at night and minimum saturation. It is of note that the Norris Bulbar Score was significantly lower (poor bulbar function) in the pressure targeted group which may have influenced their secondary outcomes.
A study looking at tolerance of volume ventilation in ALS enrolled 87 patients who were initiated as inpatients. 116 Results showed that it was well tolerated by 92% of patients at 3 month assessment. The 8% who were intolerant were readmitted at 3 months for further habituation and remained intolerant. There was no comment on whether alternate modes were tried in the intolerant patients.
Prior studies have assessed ventilator pressure settings, including PEEP and EPAP. One evaluated the use of PEEP or end expiratory pressure in a dual limb circuit set up with a pressure targeted mode of ventilation. 117 End expiratory pressure of zero vs 4 cm was evaluated. Leaks were higher with PEEP 4 cm. They also noted increased auto-triggering and ineffective efforts with PEEP 4 cm. Decreased N3 sleep and higher sympathetic tone were also noted with the application of end expiratory pressure. On the other hand, EPAP pressure of up to 10 cm was allowed to abolish obstructions in one study, which suggested that unresolved obstructions were associated with higher mortality. 44 A recent study compared pressure support ventilation with volume assured pressure support (VAPS) in a retrospective review of ALS patients. 118 215 patients using pressure support were compared to 56 patients on volume assured pressure support. Both modes were well tolerated. Volume was more consistent with the volume assured group. It is likely the VAPS device was favored because the IPAP pressures in the pressure support mode were relatively low and the inspiratory times short (approximately 1 sec) and the rise times >600 msec, predisposing to smaller tidal volumes in those without a target volume.
Spontaneous timed (S/T) mode was compared to spontaneous (S) mode bilevel ventilation 119 in ALS patients and was found to improve gas exchange, respiratory events and patient ventilator synchrony when compared to the S mode.
Use of daytime mouthpiece ventilation 120 and nighttime bilevel pressure ventilation with a mask has been reported in a series of selected ALS patients. The authors defined this mode as an option in patients without significant bulbar dysfunction who require 24 hour ventilation. They noted that patients derived the greatest survival benefit if they could generate an assisted PCF > 180 L/min at initiation of mouthpiece ventilation.
Another question that remains unanswered is the optimal way to titrate NIV or to determine appropriate ventilator settings in this population. Many older studies did not describe how the ventilator settings were determined. Polysomnography to establish ventilator settings was previously rarely reported. More recently an ambulatory outpatient model of NIV initiation was described that involved an empiric daytime titration followed in 4-6 weeks by polysomnography for further titration. 75 Their comparator was an inpatient initiation model. The outpatient model showed shortened wait times for ambulatory initiation of NIV and improved survival. Other groups continue to admit patients for titrations and habituation. In the study by Martinez looking at tolerance of volume control ventilation, length of stay averaged 4.7 days for inpatient initiation of NIV. 116 Regardless of the method of initial titration, follow-up to assure adequate ventilation is suggested by 2 recent studies 43, 44 reporting shortened survival with ineffective ventilation. Attention to initial titration and follow-up at 1, 3 and 6 months for evaluation and adjustment is suggested. In these studies, ventilator download with associated oximetry was used to assess adequacy of ventilation. there specific modes or settings that improve:
1. adherence 2. patient comfort 3. gas exchange 4. survival?
Conclusions
There are limited data comparing modes of NIV, settings or initiation protocols. There is a trend in many centres across the world to use pressure targeted ventilators which generally can be purchased at lower cost than ventilators providing volume control ventilation. Pressure targeted and volume targeted modes had similar survival in one recent study. Volume controlled modes, however, offered some advantages in symptom control, gas exchange and nocturnal oxygenation, but the study specifically addressing this noted a lower Norris bulbar score in the pressure targeted group which may have influenced the effectiveness of ventilation. Pressure support is often felt to be better tolerated than volume control modes, though one study showed that 92% of patients tolerated a volume control mode. When using a pressure targeted ventilator, the mode should control inspiratory time for both spontaneous and machine delivered breaths.
Both inpatient and outpatient protocols for NIV initiation have been reported and both are effective, though outpatient initiation may be preferred by patients and associated with better survival (possibly because of a shorter duration to initiation) and less cost.
Recommendations:
1. We recommend S/T mode Ã over S mode when delivering ventilation with pressure targeted devices. (GRADE 1C) 2. No recommendation can be made for the preferred location of the initial titration (outpatient initiation, sleep lab, or inpatient admission are all acceptable); however, delays should not be incurred irrespective of selected location. (GRADE 1C) 3. Volume-controlled ventilation is an acceptable mode and we recommend that it be used if pressure targeted modes are not tolerated or ineffective. (GRADE 1C) 4. In patients with intact bulbar function who are receiving nocturnal ventilation, we recommend use of mouthpiece ventilation rather than tracheostomy when additional daytime ventilation is required. A nasal interface may be acceptable if preferred.
(GRADE 1C)
* Clinical remarks:
Although S/T mode may improve gas exchange, respiratory events and synchrony when compared to S mode, care must be taken to assure that Ti (inspiratory time) is sufficiently long to provide adequate tidal volume and minute ventilation. In the S/T mode where the Ti is not controlled during spontaneous breaths, Ti may be too short to provide adequate tidal volume. If the percentage of triggered breaths is high, adequate support and ventilation may not be achieved. This can be resolved by use of the PC mode on ventilators that do not control Ti when the patient is triggering the device or breathing above the set rate. Other devices will control Ti on all breaths and an adequate inspiratory time may be achieved by setting a sufficiently long minimum Ti. Recommended Ti in neuromuscular patients without underlying airways disease is 1.2 to 1.5 seconds: up to a 1:1 ratio which is dependent on respiratory rate. (expert consensus)
Summary
There is increasing evidence of benefit of HMV in patients with ALS. The current guideline reviews reported benefits and seeks to advise on monitoring of respiratory status in ALS and timing of initiation of noninvasive ventilation.
There is limited evidence on optimal settings and modes for patients using NIV in ALS though a timed or controlled mode is preferred. Tracheostomy remains an option for well-informed patients with ALS, but is associated with a high burden of care. Respiratory muscle training has not been shown to offer clear benefit and cannot be recommended at this time. RCTs, completed since the last publication of this guideline and addressing diaphragm pacing in ALS, have shown harm and pacing is not advised. Much research remains to be done. Device download remotely is increasingly available and its use to improve outcomes requires further assessment. Optimal timing of NIV to optimize benefit remains an ongoing question, in particular in bulbar predominant ALS.
The intention of the CTS guideline panel for HMV is to report on changes to this guideline going forward as new evidence is published and reviewed, creating a "living document" available on the CTS website.
Implementation
The most relevant and important of the recommendations are those addressing monitoring before and after initiation of NIV and indications for initiation of noninvasive ventilation (PICO question 2).
Implementation of these recommendations
1. Wide dissemination given the variety of care providers for ALS patients An abridged online and electronic copy "quick reference" guide with reference link to the full document will be circulated to key stakeholders involved in care of the ALS patient. 
ALS clinic interaction nationally
Authors of this guideline are from across Canada and can present locally to respirologists, neurologists, physiatrists and ALS clinics. Annually, there is a national ALS Research symposium hosted by ALS Canada with participants and clinical leaders from centres across Canada. These guidelines will be presented, and a poster of the abridged recommendations and links will be available throughout the meeting.
Every ALS Clinic in Canada has representation at the Canadian ALS Research Network, and is typically linked to their respective provincial societies, and to ALS Canada. This strong network between researchers, clinicians, community advocates and patients/families will be instrumental in ensuring broad dissemination.
Cost considerations
The aforementioned strategies are associated with minimal cost implications and maximal impact. The primary cost may be related to the purchase of equipment recommended for monitoring which is associated with a minimal initial cost outlay, but may have ongoing cost associated with disposables.
Measures of successful implementation and dissemination
As care of the individual with ALS may be by individual neurologists, physiatrists, respirologists or ALS centres, it will be challenging to monitor adoption of the guideline. The most reliable data collection at present is by ALS clinics and by the Canadian ALS research network and it is for this reason that a survey of compliance will be done through ALS clinics and the research network. At 12-24 months post publication and distribution, ALS clinics across Canada will be surveyed to assess their knowledge of and compliance with recommendations.
Current gaps and future research needs
The guideline panel identified areas where further research would improve the ability of clinicians to optimally manage patients with ALS.
1. Evaluation of device download driven setting changes (both remotely and at clinic assessments) to improve outcomes such as adherence, optimal ventilation, hospital admissions and survival. 2. Ongoing evaluation of optimal timing, in particular, in bulbar predominant patients.
